The two index heavyweights Nestlé and Roche presented their quarterly figures last Wednesday; both traditional companies were convincing with their results.
Nestlé reported organic sales growth of 7.6%, beating not only analysts' expectations but also the results of rival Danone. Almost 70% of analysts recommend buying the stock, 30% expect market performance. ZKB Equity Research rates the stock as "overweight".
Roche's two divisions (Pharmaceuticals and Diagnostics) are also presenting strong quarters, which has enabled the group to revise its sales forecasts upwards. Roche also receives an "overweight" rating from ZKB Equity Research.
Accordingly, the market consensus forecasts an upward trend for these two stocks - In the case of barrier products, the probability of a barrier hit is thus assessed as lower while the coupon remains unchanged.
Callable BRC on Nestlé and Roche
Callable BRC on Nestlé and Roche
Capped Outperformance Certificate on Roche
*indicative
ZKB Autocallable Barrier Reverse Convertible on worst of Baloise-Holding AG/Swiss Life Holding AG/Zu... 134141312 / CH1341413123 |
ZKB Reverse Convertible auf DocMorris AG 132913889 / CH1329138890 |
ZKB Autocallable Barrier Reverse Convertible on worst of The Kraft Heinz Company/Coca-Cola Co/McDona... 130400379 / CH1304003796 |
10.8715% p.a. ZKB Barrier Reverse Convertible, 28.12.2026 auf DOCM SE 130397955 / CH1303979558 |
ZKB Barrier Reverse Convertible on worst of Danone SA/Nestlé AG/Mondelez International Inc/The Kraft... 130399823 / CH1303998236 |